{"url_path":"/sec/pbsv/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005986-index.html","accession_number":"0001654954-26-005986","cik":"0001304161","ticker":"PBSV","issuer_name":"Pharma-Bio Serv, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005986-index.html","primary_entity_key":"0001304161","primary_entity_name":"Pharma-Bio Serv, Inc."},"word_count":618,"has_tables":true,"body_markdown":"pbsv_10q.htm\n0001304161false--10-31Q220260.000110000000000.000150000000falsefalsefalsefalse530000037335029335000013041612025-11-012026-04-300001304161pbsv:OtherSegmentMember2025-11-012026-04-300001304161pbsv:OtherSegmentMember2025-02-012025-04-300001304161pbsv:OtherSegmentMember2026-02-012026-04-300001304161pbsv:OtherSegmentMember2024-11-012025-04-300001304161pbsv:EuropeConsultingMember2025-11-012026-04-300001304161pbsv:EuropeConsultingMember2025-02-012025-04-300001304161pbsv:EuropeConsultingMember2026-02-012026-04-300001304161pbsv:EuropeConsultingMember2024-11-012025-04-300001304161pbsv:UnitedStatesConsultingMember2025-11-012026-04-300001304161pbsv:UnitedStatesConsultingMember2025-02-012025-04-300001304161pbsv:UnitedStatesConsultingMember2026-02-012026-04-300001304161pbsv:UnitedStatesConsultingMember2024-11-012025-04-300001304161pbsv:PuertoRicoConsultingMember2025-11-012026-04-300001304161pbsv:PuertoRicoConsultingMember2025-02-012025-04-300001304161pbsv:PuertoRicoConsultingMember2026-02-012026-04-300001304161pbsv:PuertoRicoConsultingMember2024-11-012025-04-300001304161us-gaap:AccountsReceivableMemberpbsv:GlobalLevelCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMemberpbsv:GlobalLevelCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMemberpbsv:GlobalLevelCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMemberpbsv:GlobalLevelCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelFourCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelThreeCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelTwoCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:GlobalLevelOneCustomerMember2025-02-012025-04-300001304161us-gaap:AccountsReceivableMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:EuropeConsultingMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:UnitedStatesConsultingMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:PuertoRicoConsultingMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:FourCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:ThreeCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2025-11-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:TwoCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2025-02-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2026-02-012026-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2024-11-012025-04-300001304161us-gaap:SalesRevenueNetMemberpbsv:OneCustomerMember2025-11-012026-04-3000013041612025-01-2800013041612025-01-012025-01-280001304161us-gaap:EmployeeStockOptionMember2025-11-012026-04-300001304161us-gaap:EmployeeStockOptionMember2026-02-012026-04-300001304161us-gaap:EmployeeStockOptionMember2025-02-012025-04-300001304161us-gaap:EmployeeStockOptionMember2024-11-012025-04-300001304161pbsv:PRIDCOMember2011-06-012011-06-300001304161pbsv:PRIDCOMember2025-11-012026-04-300001304161pbsv:TaxReformMember2025-07-012025-07-040001304161pbsv:TaxReformMember2017-12-220001304161pbsv:TaxReformMember2017-12-012017-12-220001304161us-gaap:TreasuryStockCommonMember2026-02-012026-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-02-012026-04-300001304161us-gaap:RetainedEarningsMember2026-02-012026-04-300001304161us-gaap:AdditionalPaidInCapitalMember2026-02-012026-04-300001304161us-gaap:PreferredStockMember2026-02-012026-04-300001304161us-gaap:CommonStockMember2026-02-012026-04-3000013041612026-01-310001304161us-gaap:TreasuryStockCommonMember2026-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-310001304161us-gaap:RetainedEarningsMember2026-01-310001304161us-gaap:AdditionalPaidInCapitalMember2026-01-310001304161us-gaap:PreferredStockMember2026-01-310001304161us-gaap:CommonStockMember2026-01-310001304161us-gaap:TreasuryStockCommonMember2026-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-300001304161us-gaap:RetainedEarningsMember2026-04-300001304161us-gaap:AdditionalPaidInCapitalMember2026-04-300001304161us-gaap:PreferredStockMember2026-04-300001304161us-gaap:CommonStockMember2026-04-300001304161us-gaap:TreasuryStockCommonMember2025-11-012026-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-11-012026-04-300001304161us-gaap:RetainedEarningsMember2025-11-012026-04-300001304161us-gaap:AdditionalPaidInCapitalMember2025-11-012026-04-300001304161us-gaap:PreferredStockMember2025-11-012026-04-300001304161us-gaap:CommonStockMember2025-11-012026-04-300001304161us-gaap:TreasuryStockCommonMember2025-10-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-10-310001304161us-gaap:RetainedEarningsMember2025-10-310001304161us-gaap:AdditionalPaidInCapitalMember2025-10-310001304161us-gaap:PreferredStockMember2025-10-310001304161us-gaap:CommonStockMember2025-10-310001304161us-gaap:TreasuryStockCommonMember2025-02-012025-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-02-012025-04-300001304161us-gaap:RetainedEarningsMember2025-02-012025-04-300001304161us-gaap:AdditionalPaidInCapitalMember2025-02-012025-04-300001304161us-gaap:PreferredStockMember2025-02-012025-04-300001304161us-gaap:CommonStockMember2025-02-012025-04-3000013041612025-01-310001304161us-gaap:TreasuryStockCommonMember2025-01-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-310001304161us-gaap:RetainedEarningsMember2025-01-310001304161us-gaap:AdditionalPaidInCapitalMember2025-01-310001304161us-gaap:PreferredStockMember2025-01-310001304161us-gaap:CommonStockMember2025-01-3100013041612025-04-300001304161us-gaap:TreasuryStockCommonMember2025-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-300001304161us-gaap:RetainedEarningsMember2025-04-300001304161us-gaap:AdditionalPaidInCapitalMember2025-04-300001304161us-gaap:PreferredStockMember2025-04-300001304161us-gaap:CommonStockMember2025-04-300001304161us-gaap:TreasuryStockCommonMember2024-11-012025-04-300001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-11-012025-04-300001304161us-gaap:RetainedEarningsMember2024-11-012025-04-300001304161us-gaap:AdditionalPaidInCapitalMember2024-11-012025-04-300001304161us-gaap:PreferredStockMember2024-11-012025-04-300001304161us-gaap:CommonStockMember2024-11-012025-04-3000013041612024-10-310001304161us-gaap:TreasuryStockCommonMember2024-10-310001304161us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-310001304161us-gaap:RetainedEarningsMember2024-10-310001304161us-gaap:AdditionalPaidInCapitalMember2024-10-310001304161us-gaap:PreferredStockMember2024-10-310001304161us-gaap:CommonStockMember2024-10-3100013041612024-11-012025-04-3000013041612025-02-012025-04-3000013041612026-02-012026-04-3000013041612025-10-3100013041612026-04-3000013041612026-06-10iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n  \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n** WASHINGTON, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n(Mark One)\n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES** **EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended **April 30, 2026**\n\nor\n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from _____________ to ______________\n\n \n\nCommission File No. **000-50956**\n\n \n\n**PHARMA-BIO SERV, INC.**\n\n(Exact Name of Registrant as Specified in Its Charter)\n\n \n\n **Delaware**\n\n \n\n **20-0653570**\n\n (State or Other Jurisdiction of\n\nIncorporation or Organization)\n\n \n\n* * (IRS  Employer\n\n Identification No.)\n\n \n\n**Pharma-Bio Serv**\n\n**PO Box 1049**\n\n**Dorado, Puerto Rico**\n\n \n\n**00646**\n\n(Address of Principal Executive Offices)\n\n \n\n(Zip Code)\n\n \n\n**787-278-2709**\n\n(Registrant’s Telephone Number, Including Area Code)\n\n \n\n**N/A**\n\n  (Former name, former address and former fiscal year, if changed since last report)  \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:  **None**\n\n \n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which registered\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company\n\n☐ \n\n                                                                                                                         \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐     No ☒\n\n \n\nThe number of shares of the registrant’s common stock outstanding as of June 10, 2026 was 22,901,692.\n\n \n\n \n\n \n\n \n\n**PHARMA-BIO SERV, INC.**\n\n**FORM 10-Q**\n\n**FOR THE QUARTER ENDED APRIL 30, 2026**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n\n**Page**\n\n \n\n**PART I FINANCIAL INFORMATION**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1 – Financial Statements](#i1)\n\n \n\n3\n\n \n\n \n\n \n\n \n\n \n\n[Condensed Consolidated Balance Sheets as of April 30, 2026 and October 31, 2025 (unaudited)](#bs)\n\n \n\n3\n\n \n\n \n\n \n\n \n\n \n\n[Condensed Consolidated Statements of Operations for the three-month and six-month periods ended April 30, 2026 and 2025 (unaudited)](#cso)\n\n \n\n4\n\n \n\n \n\n \n\n \n\n \n\n[Condensed Consolidated Statements of Comprehensive Income for the three-month and six-month periods ended April 30, 2026 and 2025 (unaudited)](#income)\n\n \n\n5\n\n \n\n \n\n \n\n \n\n \n\n[Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three-month and six-month periods ended April 30, 2026 and 2025 (unaudited)](#equity1)\n\n \n\n6\n\n \n\n \n\n \n\n \n\n \n\n[Condensed Consolidated Statements of Cash Flows for the three-month and six-month periods ended April 30, 2026 and 2025 (unaudited)](#cf)\n\n \n\n8\n\n \n\n \n\n \n\n \n\n \n\n[Notes to Condensed Consolidated Financial Statements (unaudited)](#notes)\n\n \n\n9\n\n \n\n \n\n \n\n \n\n \n\n[Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2)\n\n \n\n16\n\n \n\n \n\n \n\n \n\n \n\n[Item 4 – Controls and Procedures](#i4)\n\n \n\n19\n\n \n\n \n\n \n\n \n\n \n\n**PART II OTHER INFORMATION**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 1 – Legal Proceedings](#p2i1)\n\n \n\n20\n\n \n\n \n\n \n\n \n\n \n\n[Item 1A – Risk Factors](#p2i1a)\n\n \n\n20\n\n \n\n \n\n \n\n \n\n \n\n[Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds](#p2i2)\n\n \n\n20\n\n \n\n \n\n \n\n \n\n \n\n[Item 6 – Exhibits](#i16)\n\n \n\n21\n\n \n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\n22\n\n \n\n \n\n \n\n2\n\n*Table of Contents*\n\n  \n\n**PART I – FINANCIAL INFORMATION**"}